API Holdings (PharmEasy) Limited Share Price | Live Update | Company Overview

Buy

₹ 40

Sell

₹ 47.5

Fairly Valued

Company Overview

By solving the accessibility problem to medicines and healthcare services, API Holdings (PharmEasy) has emerged as India’s largest online marketplace for pharma products and healthcare services in terms of GMV of products and services sold on the platform.  

Started in 2015, API Holdings (PharmEasy) has progressed from wholesaler of pharma products to fully-integrated, digital healthcare platform selling drugs, medical devices, diagnostic tests, tele-consultations.  

The company connects the chemist shops, wholesalers, medical device companies, diagnostic labs, hospitals with the consumers to reach 25 million registered users, covering 97% pin code coverage of India. There are 87k pharmacies, 3200 wholesalers and 4600 doctors registered on PharmEasy marketplace, generating annual GMV of ₹ 78 billion (2021), 10 million digital prescriptions, 3.5 million e-consultations, 565000 daily clinical investigations. 

The healthcare industry in India is least technology-disrupted. The size of the online pharmacy industry is around 2-4% of the market size as of 2020 against 12-17% in the USA, and 25-30% in China. The Indian online pharmacy industry is split between at-home delivery of prescription drugs, generic OTC medicine, diagnostics, and e-consultation. Among these, the share of e-prescription drugs is 55%, followed by 35% market share of e-OTC segment and e-consultation and e-diagnostic segments account for 6% and 4% market share respectively. 

In October, 2021, API Holdings (PharmEasy) raised about $ 350 million in its latest financing round before filing its DRHP at the valuation of $ 5.6 billion. The lead investors were Singapore based  Amansa Capital, Blackstone, US hedge fund Janus Henderson, OrbiMed, and Abu Dhabi’s sovereign wealth fund ADQ.

Checkout the latest API Holdings share price.

API Holdings (PharmEasy) Corporate Journey

YearBusiness Profile
2012Founders started retail pharmacy and wholesale supplier to hospitals.
2013Launched Ascent and pivoted to pharma distribution business.
2015Developed proprietary mobile and web application technology that powers PharmEasy online marketplace.
2016Launched docon, EMR solution provider for doctors and clinics.
2017Launched Retailio, online pharma supply chain platform for pharmacies and medicine distributors.
2020Ascent and other subsidiaries merged to form API holdings.
2021Purchased Medlife, one of the India’s leading digital healthcare company.
2021Purchased Thyrocare, India’s largest diagnostic test provider.
2021Purchased Aknamed, India’s largest online supplier of pharmaceutical and medical consumables to hospitals, clinics and medical centres.

API Holdings (PharmEasy) Business Model

API Holdings (PharmEasy) make their money from 3 sources:

1) Wholesaling of pharmacy, OTC, surgical products, private label medical products, medical consumables and other health products. The company buys from pharmaceutical companies and wholesalers and wholesale to retailers, chemists and hospitals.  The company distributes pharma products to retailers, who are registered resellers on PharmEasy marketplace. 

2) Sale of medical diagnostic services to hospitals, diagnostic companies, clinics and consumers including PharmEasy marketplace. 

3) Other sources like advertisement and lead generation on its Retailio, online pharma supply chain platform, sale of Redbook software to pharmacies, license and platform fees (from Axelia for the use of brand and technology). 

Besides, API Holdings (PharmEasy) also earns from logistics services by providing last mile delivery services for fulfilling orders on PharmEasy marketplace and lease of EMR software and hardware to doctors.

Registered Address

The registered office of API Holdings (PharmEasy) is located at 9th Floor, Raheja Plaza 1, B-Wing, L.B.S. Marg, Ghatkopar West, Mumbai, India.

SymbolAPI Holdings (PharmEasy) Ltd.
Face Value (₹):1
ISIN:INE0DJ201029
Demat Status:NSDL & CDSL
Lot Size:150 Shares

Board of Directors

NameDesignationProfile
Siddharth ShahMD & CEONA Final 1
Aditya PuriChairman & Non-Executive DirectorNA Final 1
Harsh ParekhWholetime DirectorNA Final 1
Dharmil ShethWholetime DirectorNA Final 1
Ashutosh SharmaNon-Executive DirectorNA Final 1
Ankur ThadaniNon-Executive DirectorNA Final 1
Deepak VaidyaIndependent DirectorNA Final 1
Vineeta RaiIndependent DirectorNA Final 1

Key Business Highlights

  • Owns PharmEasy, India’s largest digital marketplace for Pharma products and healthcare services in terms of gross merchandise value (GMV) of products sold. 
  • 87K active pharmacies, 3200 wholesalers, 4600 doctors, 900 Hospitals generated annual revenues of ₹2360 crores on GMV of ₹78 billion, 10million digital prescriptions, 565k daily clinical investigations, 3.4 million e-consultations during FY 2020-21. 
  • Full-stack presence across healthcare value-chain with PharmEasy (India’s largest digital pharmacy & health services marketplace), Thyrocare (India’s largest diagnostic company), Aknamed (India’s largest hospital-focussed supply chain platform) and investment in Marg ERP Ltd (India’s largest ERP provider for pharmacies and wholesalers). 
  • API Holdings group company, Retailio, is a digital pharma supply chain platform connecting pharmacies with wholesalers and manufacturers. Retailio is used by 87k pharmacies and 3200 wholesalers across 191 cities. 
  • Valued at $5.6 billion in its latest funding round in October, 2021 and backed by blue-chip investors- Naspers Ventures, Macritchie Investments, TPG Growth, Evermed Holdings.

Financial Highlights

Particulars2020-212019-20
Total Income (₹ Crores)2,360737
PAT (₹ Crores)-641-335
Diluted EPS (₹)-206.77-129.15
Book Value per Share (₹)1,39824,600
Equity (₹ Crores)3,581246

Financial Charts

Historical Chart

Shareholding Pattern

Peer Comparison

While API holdings has a fully-integrated business model focusing on pharmaceutical distribution, its online-pharmacy business, PharmEasy, competes with many unlisted players:  

  • 1mg (acquired by Tata Digital)
  • Netmeds (acquired by Reliance Retail)
  • Amazon pharmacy
  • Apollo Pharmacy
  • Easymedico.com
  • Dhani pharmacy
  • Practo

Media Updates

“Piramal Capital ties up with API Holdings”

Piramal Capital & Housing Finance (PCHFL) has tied up with API Holdings to provide financing solutions to customers and has earmarked ₹100 crore for disbursement by the end of this fiscal. Piramal Capital & Housing Finance Limited (PCHFL), the wholly owned subsidiary of Piramal Enterprises, has forged a strategic partnership with API Holdings through its digital platform Retailio, a release said on Thursday.

Retailio is India’s largest digital B2B healthcare platform. The partnership aims at synergizing respective capabilities to provide efficient and seamless financing solutions to consumers, retailers and merchants in the API Holdings’ healthcare ecosystem. 

Read more: https://economictimes.indiatimes.com/markets/stocks/news/piramal-capital-ties-up-with-api-holdings/articleshow/87920949.cms

“PharmEasy aims for $9 billion valuation via public offering”

Online drugstore PharmEasy, which bought diagnostic chain Thyrocare in June, aims to raise a billion dollars at a valuation of $9 billion in its initial public offering later this year, two people directly aware of the company’s plans said.

Read more: https://www.hindustantimes.com/business/pharmeasyaimsfor9billion-valuation-via-public-offering-101629165764182.html

Frequently Asked Questions (FAQs) on API Holdings (PharmEasy) Technologies Unlisted Shares

The buying and selling of unlisted shares and pre-IPO shares is fully legal and valid.

The procedure to buy the API Holdings (PharmEasy) shares is fairly simple. Once you have settled on the price and quantity of the transaction, you would have to transfer the funds into the bank account of the seller. Once the funds are transferred and transaction details are shared with the seller, your demat account will be credited with the shares either on the same day of the fund transfer or before the end of the next working day. 

In the secondary market, the transactions related to unlisted shares take place with the existing owners of the shares who are generally the employees or existing investors in the company. The company itself is not directly involved. 

The API Holdings (PharmEasy) unlisted shares will get credited either the same day or before the end of the next working day when you transfer the funds into our bank account.

The minimum lot size varies on the basis of market conditions and demand and supply factors. To know the current lot size for API Holdings (PharmEasy), please visit the stock page on our website: www.delistedstocks.in/current-offerings/api-holdings-pharmeasy-limited/

There are many factors which influence the pricing of unlisted shares. Apart from the supply and demand factors, the latest transactions happened on the same stock, last funding round of the company, and valuation level of companies of the similar size affect the pricing of the unlisted shares. 

Before IPO, there is no restriction on sale and transfer of your API Holdings (PharmEasy) unlisted shares. But once the shares are listed on the stock exchange, for retail investors, there is a minimum lock-in period 6 months after listing on the stock exchange. 

Once the selling price and quantity of shares is agreed with us, we will provide you with an UTR (Unique Transaction Reference) number to transfer the shares. Once you have transferred the shares into our company’s demat account, funds are released into your bank account within 24 hours or before the end of the next working day of the transfer of the shares. 

If your holding period is less than 2 years, then such income is treated as business income and liable to get taxed as per tax slab of the investor. If your holding period is more than 2 years, then your profits would be subject to long-term capital gains tax. The current short-term capital gain tax rate is 20% after indexation.

The trading in unlisted shares is governed by Securities & Contract (Regulation) Act, which comes under the preview of SEBI.  The SEBI regulations become applicable when the stocks of the company get listed on the stock exchange. There is a minimum lock-in period of 6 months for pre-IPO investors. 

The major risk associated with investing in unlisted stocks is the liquidity risk. The possible exit route for investors is either to sell to another investor or wait till the company gets listed on the stock exchange. 

Yes, NRI’s can also buy and sell API Holdings (PharmEasy) Ltd. unlisted shares just like domestic investors. But their investment is on a non-repatriable basis.

Leave Your Message

Copyright © 2021 Delisted Stocks | Powered By EGS
1